Health Technology Assessment (HTA)

Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.

Old calculator
Publication

The impact of inflation on incremental costs in HTA

4 June 2026

Inflation reshapes the economic landscape in which new treatments are evaluated. Yet cost-effectiveness thresholds tend to remain fixed over time. This report examines how inflation in…

salonica umbrellas metallic street art sea fountain rain cloudy sky greece
Insights

One Europe, one assessment? Unpacking the European Joint Clinical Assessment

28 May 2026

As the first EU Joint Clinical Assessment reports approach, national HTA systems across Europe are already adapting to a new era of coordinated clinical evaluation.

Header: 'Should HTA look beyond the healthcare system?' on lavender background with two circular headshots (Chris Skedgel, Director; Grace Hampson, Director) and the 'A DOSE OF ECONOMICS' logo surface in lime.
Podcast

Should HTA look beyond the healthcare system?

26 May 2026

Grace Hampson is joined by Chris Skedgel, a Director at OHE, to dig into one of health economics’ most contested methodological debates: what are health systems trying to achieve through…

Intro slide: headshots of Patricks Hopkinson and Matthias Hofer on a purple background with captions, accompanying article header about joint clinical assessment and access to medicines.
Podcast

Can joint clinical assessment speed up access to medicines?

19 May 2026

Grace Hampson is joined by Patrick Hopkinson, founder of PHTA Consulting and global market access expert, and Matthias Hofer, Senior Principal Economist at OHE, to take…

Large-format panorama of night windows of a brick, town apartment house
Insights

Valuing patient and carer time in HTA: equity and opportunity cost 

15 May 2026

We address two criticisms of valuing patient and carer time in HTA: that it would displace health outcomes by misallocating a fixed budget, and that it would introduce inequities based on individual productivity or income. We argue that patient and carer time are vital inputs to healthcare, and that ignoring them reduces rather than improves both efficiency and fairness.

Car light trails on winding road through the highlands near Glen
Publication

The value of fast diagnostics in time-critical infections

20 April 2026

Advancing earlier intervention in time‑critical infections Sepsis continues to impose a substantial global burden, with millions of cases and high mortality each year. Patients with bloodstream…

Cell microscopic- weevil rye
Publication

Evaluating novel antimicrobials within EU joint clinical assessments 

16 April 2026

Antimicrobial resistance (AMR) is a growing global health and economic threat. It is responsible for an additional 9.5 million hospital days and costs across the European Union (EU) and European Economic Area (EEA) economies €11.7 billion annually.

Osaka Castle and full cherry blossom with Fuji mountain backgr
Insights

Around the World in HTAs: Japan – An algorithmic approach to containing costs

14 April 2026

Japan’s health technology assessment (HTA) system uses algorithmic drug pricing and cost-effectiveness analysis to manage rising healthcare costs while maintaining universal access and innovation.

Event

Masterclass: Cost-effectiveness thresholds in health technology assessment

8 April 2026

Join us for an in‑depth Masterclass that unpacks one of the most influential—and often misunderstood—elements of health technology assessment: cost‑effectiveness thresholds. Across the world, thresholds shape…